Melanoma - B16F10 Cells

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Skin cancers include carcinomas of all layers of the skin with the most common being basal cell (BCC) and squamous cell carcinomas (SCC). Melanoma and non-melanoma skin cancers are much less common. Of all the skin cancer types, melanoma is a serious form of skin cancer that begins in melanocytes, the melanin-producing neural crest-derived cells located in the bottom layer (the stratum basal) of the skin’s epidermis. While malignant BCC and SCC are rarely metastatic, the less common malignant melanoma is highly aggressive and spreads rapidly to other parts of the body. Melanomas present in many different shapes, sizes and colors with a comprehensive set of warning signs.

The B16 syngeneic mouse model of melanoma is the most commonly use metastatic melanoma model for preclinical studies. We have established the syngeneic B16F10 mouse melanoma model to evaluate response to immune-oncology agents and support development of novel therapeutics. The B16f10 cell line was generated as the 10th serial passage subclone of the B16 parent tumor line in C57BL/6 mice. In vitro, these cells grow as an adherent population taking on an epithelial morphology. In vivo, intradermal implant of B16F10 cells in C57BL/6 mice results in aggressively growing tumors. Our growth studies show efficient growth kinetics following a range of inocula with doubling time of approximately 2-3 days. Control animals stay on study for 20-25 days before they reach euthanasia criteria of excessive tumor burden. This results in a model which can facilitate up to two-week dosing window for test agents to elicit their anti-tumor activity. While the model itself does not result in reduction of body weight, tumor scabbing and ulcerations are common clinical symptoms associated with subcutaneous and intradermal B16F10 tumor growth.

Growth kinetics validation.  2.5 x 10B16F10 mouse melanoma cells (derived from C57BL/6 mice) were subcutaneously injected into the rear flank of C57BL/6 mice. Tumor growth volume was monitored approximately twice / week using calipers (Data are mean± SEM; n=20).

The B16F10 mouse model is run subcutaneously.   In addition to tumor volume a variety of additional physiological parameters and biomarkers, such as cytokine levels,  can be incorporated into the study design.  Study durations can range from 3  – 5weeks.